Several funds still made big bets on some major holdings.
Stephen TaubApril 18, 2023
After racing off to a strong start, most biopharma hedge funds posted a second straight month of sharp losses in March, a period in which many tech and other stocks posted healthy gains. In fact, most
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.